<DOC>
	<DOC>NCT02658188</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of ASP8825 (gabapentin enacarbil) for long-term treatment of restless legs syndrome patients.</brief_summary>
	<brief_title>Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Patients who diagnosed with RLS according to the diagnostic criteria established by the International RLS Study Group International Restless Legs Syndrome Scale (IRLS) score ≥15 presence of RLS symptoms on ≥15 days per month and ≥4 days per week preceding inclusion in this study Patients using dopamine agonists or gabapentin within 1 week before or any antiRLS treatment within 2 weeks before the start of the pretreatment observation period Patients with an estimated creatinine clearance &lt;60 mL/min determined using the CockcroftGault formula Pregnant or lactating women Individuals with serum ferritin &lt;20 ng/mL were also excluded from the trial Individuals with movement disorders and/or abnormal neurological findings</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Restless legs syndrome patients</keyword>
	<keyword>ASP8825</keyword>
	<keyword>XP13512</keyword>
</DOC>